Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 20.06% | 2.61% | -39.06% | -89.42% | -73.14% |
| Total Depreciation and Amortization | 23.74% | 73.47% | 129.36% | 148.18% | 101.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -25.18% | -6.90% | 52.99% | 133.99% | 146.95% |
| Change in Net Operating Assets | -259.44% | 172.62% | 129.27% | 100.54% | 144.24% |
| Cash from Operations | 8.50% | 17.46% | -3.52% | -38.81% | -15.54% |
| Capital Expenditure | 83.50% | 44.84% | 52.76% | 54.90% | -1.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 390,387.32% | 390,387.32% |
| Divestitures | 100.00% | 100.00% | -- | -- | -- |
| Other Investing Activities | -7.31% | -15.95% | -78.03% | -88.48% | -35.77% |
| Cash from Investing | -102.36% | -103.83% | -106.49% | 1,552.78% | 1,986.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.75% | -32.89% | -89.75% | -175.60% | -1,006.36% |
| Issuance of Common Stock | 124.70% | 45.28% | 71.33% | 7.97% | -58.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -121.50% | -198.00% | -- | -- | -- |
| Cash from Financing | 129.06% | 44.38% | 71.49% | 6.96% | -59.83% |
| Foreign Exchange rate Adjustments | -91.50% | 469.81% | 629.77% | 6,471.05% | 3,459.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.03% | -23.14% | -25.15% | 498.89% | -22.50% |